{"id":"csf-1-component-2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CSF-1 Component #2 is a component of the colony-stimulating factor 1 (CSF-1) protein, which plays a crucial role in the regulation of immune cell function, including the proliferation and differentiation of macrophages and dendritic cells. By modulating the activity of these cells, CSF-1 Component #2 may help to restore balance to the immune system and reduce inflammation.","oneSentence":"CSF-1 Component #2 is a protein that modulates immune cell function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:29:46.638Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT02584647","phase":"PHASE1, PHASE2","title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","status":"TERMINATED","sponsor":"Gulam Manji","startDate":"2015-11-04","conditions":"Sarcoma, Malignant Peripheral Nerve Sheath Tumors","enrollment":39},{"nctId":"NCT02728102","phase":"PHASE2","title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-07","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT03885011","phase":"PHASE2","title":"A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"Orasis Pharmaceuticals Ltd.","startDate":"2019-02-26","conditions":"Presbyopia","enrollment":166},{"nctId":"NCT01045460","phase":"PHASE2","title":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-01-15","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT01174082","phase":"PHASE2","title":"Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-20","conditions":"Myeloma","enrollment":2},{"nctId":"NCT00791037","phase":"PHASE1, PHASE2","title":"Vaccine Therapy in Treating Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-10","conditions":"HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer","enrollment":23},{"nctId":"NCT00548847","phase":"PHASE2","title":"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-01","conditions":"Leukemia","enrollment":15},{"nctId":"NCT00613509","phase":"PHASE2","title":"Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Melanoma, Cancer","enrollment":23},{"nctId":"NCT00499343","phase":"PHASE2","title":"G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01","conditions":"Lymphoma","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CSF-1 Component #2","genericName":"CSF-1 Component #2","companyName":"Orasis Pharmaceuticals Ltd.","companyId":"orasis-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CSF-1 Component #2 is a protein that modulates immune cell function. Used for Treatment of autoimmune diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}